Investigational New Drug

• An Investigational New Drug (IND) is an unapproved pharmaceutical product undergoing clinical trials.
• The primary purpose of an Investigational New Drug is to gather safety and efficacy data in humans.
• The investigational new drug application process is a formal submission to regulatory bodies like the FDA.
• The IND drug development stages typically involve three phases of clinical trials (Phase 1, 2, 3).
• IND status allows for the ethical and controlled study of potential new treatments before market approval.

What is an Investigational New Drug (IND)?

An Investigational New Drug (IND) refers to a pharmaceutical drug or biological product that has not yet received approval from a regulatory authority, such as the U.S. Food and Drug Administration (FDA), for commercial marketing. This designation is granted after extensive preclinical research, allowing the drug to be tested in human subjects through a series of clinical trials. The IND status is a critical regulatory milestone, enabling researchers to assess the drug’s safety, dosage, and effectiveness in a controlled environment.

Before an IND application is submitted, a drug candidate undergoes rigorous laboratory and animal testing to evaluate its pharmacological profile, toxicity, and potential therapeutic effects. This preclinical phase ensures that there is sufficient evidence to justify human trials, minimizing risks to participants. The IND application itself details the drug’s composition, manufacturing information, and results from these preclinical studies, along with the proposed clinical trial protocols.

Purpose of an Investigational New Drug

The primary purpose of an Investigational New Drug is to permit the legal shipment of an unapproved drug across state lines for the sole purpose of conducting clinical investigations. This regulatory mechanism ensures that new drugs are thoroughly evaluated for safety and efficacy before they are made available to the general public. It serves several vital functions in the drug development process:

• Patient Protection: It establishes a framework to protect the rights and safety of human subjects participating in clinical trials. This includes requirements for informed consent and ethical review by Institutional Review Boards (IRBs).
• Data Collection: It facilitates the systematic collection of data on a drug’s pharmacological effects, absorption, distribution, metabolism, excretion, and potential adverse reactions in humans.
• Efficacy Determination: Clinical trials conducted under an IND aim to determine whether a drug is effective in treating a specific condition or disease.
• Dose Optimization: Researchers use IND studies to identify the optimal dosage and administration regimen for the drug.

According to the FDA, in 2022, the Center for Drug Evaluation and Research (CDER) received over 1,000 new IND applications, highlighting the continuous effort in pharmaceutical innovation and the critical role of the IND process in bringing new therapies to patients.

The IND Application Process and Drug Development Stages

The investigational new drug application process is a comprehensive submission to the FDA, typically made by a sponsor (e.g., a pharmaceutical company or academic researcher) after successful preclinical testing. This application must include detailed information about the drug, including its chemical structure, manufacturing process, results from animal studies, and the proposed plans for human clinical trials. Once an IND application is submitted, the FDA has 30 days to review it. If the FDA does not raise any concerns, the sponsor can proceed with human clinical trials.

Following IND approval, the drug enters the IND drug development stages, which are structured into three main phases of clinical trials, each with distinct objectives:

Successful completion of Phase 3 trials, demonstrating both safety and efficacy, allows the sponsor to submit a New Drug Application (NDA) or Biologics License Application (BLA) for marketing approval. The IND process is therefore a foundational step, ensuring that only promising and thoroughly vetted drug candidates progress towards becoming approved treatments.